Laura Deming

The Longevity Fund thesis

While it’s critical for new talent to understand and recruit the most talented drug developers in the industry, traditional company-building and fundraising strategies do not obviously translate. You need to think differently to build these companies. Longevity companies will involve fundamentally new regulatory, scientific, fundraising and company-building traits. Regulatory strategies to get lifespan drugs to market don't already exist, the science specific to longevity (from how you measure aging to accumulated knowledge of which interventions are BS) isn't common knowledge in the same way

Sector and stage focus

• Seed: Medical Devices, BioTech, Health IT, Digital Health, Health & Hospital Services
• general: San Francisco Bay Area
• Pre-seed: Medical Devices, Health IT, Digital Health, BioTech, Health & Hospital Services

Is Laura Deming a fit for your round?

Upload your pitch deck and see whether Laura Deming appears in your top 20 matches.